A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)

Trial Profile

A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2014

At a glance

  • Drugs MVA 85A (Primary) ; Tuberculosis vaccine (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2014 Accrual to date is 134% according to United Kingdom Clinical Research Network
    • 16 Sep 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 10 Apr 2014 Accrual to date is 102% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top